Demant upgrades financial guidance again despite October's implant issues
Danish hearing giant Demant, which upgraded its financial guidance for the full year in August, has released an interim management statement covering the period year-to-date, in which the company has raised its financial expectations for 2021 in spite of having to recall cochlear implants a little over two weeks ago.
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY CATHERINE BRETT AND DANIEL PEDERSEN
It was a wakeup call and an economic blow when hearing aid manufacturer Demant's surgical arm Oticon Medical had to recall a number of cochlear implants in addition to halting the further production of the devices in mid October.
In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.
The US retail chain has stopped selling its own private label hearing aids – and until the next generation comes along, other hearing companies selling products via Costco are enjoying the empty shelf space.